<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03132311</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT03132311</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals</brief_title>
  <acronym>YF-HIV</acronym>
  <official_title>Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oswaldo Cruz Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oswaldo Cruz Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 4 study to evaluate the immunogenicity and Safety of the 17DD Yellow Fever vaccine in
      HIV infected individuals, compared to non-HIV-infected individuals.

      Main objective:

      To compare the proportion of seroconversion and the geometric mean of neutralizing antibodies
      30 days and 365 days after vaccine.

      Secondary objectives:

      To evaluate whether the titles of neutralizing antibodies are associated with CD4 lymphocyte
      counts, CD8 lymphocyte counts, CD4 nadir, HIV viral load and use of antiretroviral therapy.
      To assess the yellow fever vaccine viremia at day 10 after vaccine.To compare the incidence
      of adverse events in HIV-infected and non-HIV-infected individuals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 29, 2017</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>30 days after the vaccine</time_frame>
    <description>Seroconversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>30 days after the vaccine</time_frame>
    <description>Neutralizing antibodies titers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>365 days after the vaccine</time_frame>
    <description>Seroconversion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>365 days after the vaccine</time_frame>
    <description>Neutralizing antibodies titers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viremia</measure>
    <time_frame>7 days after the vaccine</time_frame>
    <description>Yellow Fever vaccine viremia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 30 days after the vaccine</time_frame>
    <description>Yellow Fever vaccine related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>5 years after the vaccine</time_frame>
    <description>Neutralizing antibodies titles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>10 years after the vaccine</time_frame>
    <description>Neutralizing antibodies titles</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV positive subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 HIV positive adults with CD4 &gt; 200 cells/mm3, stratified in 3 groups (100 patients in each group) according to CD4 counts (200-350; 351-500, &gt;500 cells/mm3).
Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV negative subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 HIV negative adults.
Assigned intervention: Yellow fever vaccination (17 DD Biomanguinhos)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Yellow Fever vaccination (17 DD Biomanguinhos)</intervention_name>
    <description>One intramuscular injection</description>
    <arm_group_label>HIV positive subjects</arm_group_label>
    <arm_group_label>HIV negative subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected adults, age &gt;= 18 and &lt;60 years old.

          -  CD4 &gt; 200 cells/mm³ within the last 6 months prior to inclusion. Individuals with no
             CD4 results in the last 6 months which have undetectable HIV viral load and last CD4
             count &gt; 350 can be included.

          -  Healthy HIV-uninfected individuals (aged &gt;= 18 and &lt; 60)

          -  No history of Yellow Fever vaccination

          -  Willing to participate and to sign the consent

        Exclusion Criteria:

          -  Individuals with chronic diseases such as: decompensated diabetes, kidney failure (in
             dialysis), liver failure/cirrhosis, cancer (except for non-melanoma skin cancer and in
             situ HIV related carcinoma), use of immunosuppressive agents (including prednisone ≥
             20mg/day, during 7 or more days in the last 30 days before inclusion).

          -  Pregnant women

          -  Hypersensitivity reaction to eggs, chicken protein. Allergy to erythomycin or
             kanamycin. Hereditary fructose intolerance.

          -  Administration of immunoglobulins or blood derivates &lt; 3 months or life attenuated
             vaccine &lt;1 month.

          -  History of thymic dysfunction (including thymoma and thymectomy).

          -  Use of anti-CCR5

          -  symptoms of severe acute illnesses or fever (axillary temperature ≥ 38°C)

          -  HIV positive rapid test for HIV negative subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lara E Coelho, MD</last_name>
    <phone>+552122707064</phone>
    <email>lara.coelho@ini.fiocruz.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Grinsztejn, MD</last_name>
    <phone>+552122707064</phone>
    <email>gbeatriz@ini.fiocruz.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Infectologia Evandro Chagas</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21040360</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lara Coelho, MD</last_name>
      <phone>+55 21 22707064</phone>
      <email>lara.coelho@ini.fiocruz.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>yellow fever vaccine</keyword>
  <keyword>hiv</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Yellow Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

